logo-loader
viewCytoDyn Inc.

CytoDyn executes agreement with American Regent for US distribution of Leronlimab as a coronavirus treatment

The move comes ahead of the data readout from CytoDyn’s clinical trials in the coronavirus space

CytoDyn Inc. - CytoDyn executes agreement with American Regent for US distribution of Leronlimab as a coronavirus treatment
CytoDyn has been granted over 60 emergency Investigational New Drug authorizations by the FDA and plans to provide clinical updates for this patient population in the coming weeks

CytoDyn Inc (OTCQB:CYDY), a late-stage biotechnology company, revealed Monday that it has signed an exclusive supply agreement with American Regent Inc for the distribution of its investigational new drug, leronlimab, for the treatment of coronavirus (COVID-19) in the US.

Under the terms of the agreement, CytoDyn will supply leronlimab to American Regent, a Daiichi Sankyo Group company, which is a top-10 injectable manufacturer, and receive quarterly payments based on a profit-sharing arrangement.

“Having this distribution agreement in place ahead of the readout from CytoDyn’s COVID-19 clinical trials further emphasizes CytoDyn’s commitment to making leronlimab immediately available to patients based on the successful completion of its ongoing clinical trials,” CytoDyn CEO Nader Pourhassan said in a statement.

READ: CytoDyn expects to hear a completion date from regulators next month for its leronlimab license application

“We are particularly happy to be partnering with a company with the proven expertise, unparalleled commercial reach and stellar reputation of American Regent,” he added.

Vancouver, Washington-based CytoDyn is currently enrolling a Phase 2b/3 clinical trial for 390 severe and critically ill COVID-19 patients, which is a randomized, 2:1 ratio active drug to placebo-controlled trial.

CytoDyn also said it has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical study for mild-to-moderate COVID-19 patients in the US.

“American Regent is looking forward to partnering with CytoDyn to provide COVID-19 patients rapid and efficient access to a potentially life-saving drug,” said American Regent chief Harsher Singh.

Leronlimab was previously granted Fast Track designation by the US Food and Drug Administration (FDA) for its indications as a treatment for metastatic triple-negative breast cancer and as part a combination therapy for HIV-infected patients.

The drug works by blocking CCR5, a cellular receptor that is important in HIV infection, tumor metastases and other diseases.

For COVID-19, the FDA has granted a so-called rolling review for the drug as part of CytoDyn's biologics license application submission. It has been granted more than 60 emergency Investigational New Drug authorizations by the FDA and plans to provide clinical updates for this patient population in the coming weeks.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: CytoDyn Inc.

Price: 4.81 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.5 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn’s Leronlimab receives positive DSMC recommendation in ongoing Phase...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan and Chief Scientific Advisor Dr Jay Lalezari joined Steve Darling from Proactive with news the company has had results from an independent Data Safety Monitoring Committee who completed its first safety review of the ongoing Phase 3 clinical trial of...

17 hours, 55 minutes ago

2 min read